Cutaneous lupus erythematosus

This study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…

This study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…

This study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…

This study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…

This study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…

This early study tests whether tapinarof cream, already approved for psoriasis, can improve skin lesions in people with cutaneous lupus. Ten adults with active lupus lesions will apply the cream daily for 16 weeks. Researchers will measure changes in skin activity and study immun…

This early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. It is too early to know if it works, but results will guide future research.

This phase 2 trial tests deucravacitinib, an anti-inflammatory pill, against a placebo in 74 adults with active discoid or subacute cutaneous lupus — skin rashes caused by lupus. The main goal is to see if the drug reduces rash severity after 16 weeks. Participants must already b…